Replies to post #961 on Bristol Myers Squibb (BMY)

[DewDiligence]

Phase-2 Deucravacitinib data in PA:

https://www.businesswire.com/news/home/20201109005145/en

[DewDiligence]

Deucravacitinib scores second phase-3 win in psoriasis:

https://www.businesswire.com/news/home/20210202005374/en/Bristol-Myers-Squibb-Announces-Positive-Topline-Results-from-Second-Pivotal-Phase-3-Psoriasis-Study-Showing-Superiority-of-Deucravacitinib-Compared-to-Placebo-and-Otezla%C2%AE-apremilast

[DewDiligence]

Deucravacitinib phase-3 data update in psoriasis—(in conjunction with AAD slide set in immediately preceding post):

https://news.bms.com/news/corporate-financial/2021/Bristol-Myers-Squibb-Presents-Positive-Data-from-Two-Pivotal-Phase-3-Psoriasis-Studies-Demonstrating-Superiority-of-Deucravacitinib-Compared-to-Placebo-and-Otezla-apremilast/default.aspx

[DewDiligence]

BMY’s Deucravacitinib fails phase-2 trial in UC:

https://finance.yahoo.com/news/bristol-myers-squibb-provides-phase-105900443.html

"While we did not achieve proof of concept in this study, we are committed to advancing our deucravacitinib clinical program in inflammatory bowel disease, including ulcerative colitis and Crohn’s disease, as well as in psoriatic arthritis, lupus and other immune-mediated diseases.